Proteonomix, Inc., formerly National Stem Cell Holding, Inc., is a biotechnology company dedicated to the development of cell therapies to treat a range of diseases. The Company’s research is focused on cosmetics, antiaging and injury. Proteonomix, Inc. is commercializing its products through its subsidiary Proteoderm, INC. The Company is also developing a platform that will allow for the growth of contaminant-free human stem (hES) cell lines, which will then be made available to the research community. Proteonomix, Inc. is engaged in the development of progenitor and stem cell therapies. It in the early stage of developing a pipeline of product candidates with the first, a cosmetic product for antiaging and damaged skin (Proteoderm). Other products include the treatment of cardiac disease and diabetes with bone marrow and umbilical cord derived stem cells. It is working to offer families a banking option that maximizes the curative potential of their baby’s umbilical cord blood.